ATE336253T1 - Vitamin-d derivate zur behandlung des systemischen lupus erythematodes - Google Patents

Vitamin-d derivate zur behandlung des systemischen lupus erythematodes

Info

Publication number
ATE336253T1
ATE336253T1 AT00923617T AT00923617T ATE336253T1 AT E336253 T1 ATE336253 T1 AT E336253T1 AT 00923617 T AT00923617 T AT 00923617T AT 00923617 T AT00923617 T AT 00923617T AT E336253 T1 ATE336253 T1 AT E336253T1
Authority
AT
Austria
Prior art keywords
vitamin
death
derivatives
treatment
systemic lupus
Prior art date
Application number
AT00923617T
Other languages
English (en)
Inventor
Hector F Deluca
Margherita T Cantorna
Jean Humpal-Winter
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Application granted granted Critical
Publication of ATE336253T1 publication Critical patent/ATE336253T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00923617T 1999-04-29 2000-04-25 Vitamin-d derivate zur behandlung des systemischen lupus erythematodes ATE336253T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30197099A 1999-04-29 1999-04-29
US09/422,571 US6673782B2 (en) 1999-04-29 1999-10-21 Treatment of systemic lupus erythematosis

Publications (1)

Publication Number Publication Date
ATE336253T1 true ATE336253T1 (de) 2006-09-15

Family

ID=26972694

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00923617T ATE336253T1 (de) 1999-04-29 2000-04-25 Vitamin-d derivate zur behandlung des systemischen lupus erythematodes

Country Status (9)

Country Link
US (2) US6673782B2 (de)
EP (1) EP1181020B1 (de)
JP (1) JP2002543115A (de)
AT (1) ATE336253T1 (de)
AU (1) AU4370900A (de)
CA (1) CA2370230C (de)
DE (1) DE60030107T2 (de)
ES (1) ES2270825T3 (de)
WO (1) WO2000066098A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479474B2 (en) * 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
EP1603530A1 (de) * 2003-03-04 2005-12-14 Teva Pharmaceutical Industries Limited Kombinationstherapie mit glatirameracetat und alphacalcidol zur behandlung von multipler sklerose
ATE537834T1 (de) * 2003-08-20 2012-01-15 Wisconsin Alumni Res Found 2-methylen-19-nor-vitamin d2-verbindungen
US20060195353A1 (en) * 2005-02-10 2006-08-31 David Goldberg Lead generation method and system
MX2007009725A (es) * 2005-02-11 2007-09-26 Wisconsin Alumni Res Found 2-metilen-19-nor-(20s-24epi)-1a, 25-dihidroxivitamina-d2.
AU2006213727B2 (en) * 2005-02-11 2011-08-18 Wisconsin Alumni Research Foundation 2-methylene-19-nor- (20S-24S) - 1alpha, 25-dihydroxyvitamin-D2
JP5665848B2 (ja) * 2009-04-17 2015-02-04 ヴィダシム・インコーポレーテッド ビタミンｄ受容体アゴニストとその使用
AU2010281391B2 (en) * 2009-08-03 2015-05-07 Wisconsin Alumni Research Foundation Method of preventing renal disease and treating symptoms thereof
SG11201408731WA (en) 2012-06-29 2015-01-29 Wisconsin Alumni Res Found USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D<sb>3</sb> TO TREAT SECONDARY HYPERPARATHYROIDISM
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US11480568B2 (en) * 2017-09-28 2022-10-25 Yeda Research And Development Co. Ltd. Diagnosis of autoimmune diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891865A (en) 1996-10-04 1999-04-06 Wisconsin Alumni Research Foundation Treatment of arthritic disease induced by infectious agents
US6030962A (en) * 1997-04-28 2000-02-29 Synttex (U.S.A.) Inc. Vitamin D3 analogs with bis C-20 side chains

Also Published As

Publication number Publication date
WO2000066098A3 (en) 2001-05-31
CA2370230A1 (en) 2000-11-09
JP2002543115A (ja) 2002-12-17
WO2000066098A2 (en) 2000-11-09
US20040142912A1 (en) 2004-07-22
EP1181020B1 (de) 2006-08-16
EP1181020A2 (de) 2002-02-27
AU4370900A (en) 2000-11-17
CA2370230C (en) 2009-12-08
DE60030107D1 (de) 2006-09-28
US6673782B2 (en) 2004-01-06
US20020028830A1 (en) 2002-03-07
ES2270825T3 (es) 2007-04-16
DE60030107T2 (de) 2007-04-19

Similar Documents

Publication Publication Date Title
IL172705A0 (en) Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
EA200001044A2 (ru) Соединения для лечения женской сексуальной дисфункции
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
ATE336253T1 (de) Vitamin-d derivate zur behandlung des systemischen lupus erythematodes
PT880350E (pt) Tratamento de esclerose multipla
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
EA200501023A1 (ru) Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
DE3586859D1 (de) Mittel zur behandlung und zum schutz der haut.
PL356252A1 (en) Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
DE602006010442D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen
NO20050718L (no) Topikal behandling av hudsykdommer
ATE141045T1 (de) Schlankmachende zusammensetzung
NO994330L (no) Metode for behandling av en tumor
CY1105564T1 (el) Θεραπεια συνδυασμου για καρκινο
NO20055390L (no) Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer
BG105875A (en) Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
ATE333897T1 (de) Arzneimittel mit chymaseinhibitoren als wirksames mittel zur behandlung von dermatitis mit zweiphasigen hautreaktionen
GEP20043231B (en) Resorcinol Composition
BR0315374A (pt) Compostos orgânicos
TR200202033T2 (tr) Epilepsi Tedavisi İçin Terkipler ve Yöntemler
DE60024408D1 (de) Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen
ATE254919T1 (de) Verwendung von penciclovir zur behandlung von menschlichem herpes virus-8

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties